57 related articles for article (PubMed ID: 7641198)
1. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity.
Aoki K; Yoshida T; Sugimura T; Terada M
Cancer Res; 1995 Sep; 55(17):3810-6. PubMed ID: 7641198
[TBL] [Abstract][Full Text] [Related]
2. YB-1 activating cascades as potential targets in KRAS-mutated tumors.
Khozooei S; Veerappan S; Toulany M
Strahlenther Onkol; 2023 Dec; 199(12):1110-1127. PubMed ID: 37268766
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of 15-bp Deletion-Type v-raf Murine Sarcoma Viral Oncogene Homolog B1 mRNA in Pancreatic Ductal Adenocarcinoma Cells Repressed Cell Growth In Vitro and Tumor Volume In Vivo.
Song J; Kobayashi Y; Asano Y; Sato A; Taniguchi H; Ui-Tei K
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804932
[TBL] [Abstract][Full Text] [Related]
4. Discovery of direct inhibitor of KRAS oncogenic protein by natural products: a combination of pharmacophore search, molecular docking, and molecular dynamic studies.
Hashemi S; Sharifi A; Zareei S; Mohamedi G; Biglar M; Amanlou M
Res Pharm Sci; 2020 Jun; 15(3):226-240. PubMed ID: 33088323
[TBL] [Abstract][Full Text] [Related]
5. Application of Direct Sonoporation from a Defined Surface Area of the Peritoneum: Evaluation of Transfection Characteristics in Mice.
Nishimura K; Yonezawa K; Fumoto S; Miura Y; Hagimori M; Nishida K; Kawakami S
Pharmaceutics; 2019 May; 11(5):. PubMed ID: 31121989
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein-biomimetic nanostructure enables efficient targeting delivery of siRNA to Ras-activated glioblastoma cells via macropinocytosis.
Huang JL; Jiang G; Song QX; Gu X; Hu M; Wang XL; Song HH; Chen LP; Lin YY; Jiang D; Chen J; Feng JF; Qiu YM; Jiang JY; Jiang XG; Chen HZ; Gao XL
Nat Commun; 2017 May; 8():15144. PubMed ID: 28489075
[TBL] [Abstract][Full Text] [Related]
7. Active macropinocytosis induction by stimulation of epidermal growth factor receptor and oncogenic Ras expression potentiates cellular uptake efficacy of exosomes.
Nakase I; Kobayashi NB; Takatani-Nakase T; Yoshida T
Sci Rep; 2015 Jun; 5():10300. PubMed ID: 26036864
[TBL] [Abstract][Full Text] [Related]
8. Novel therapeutic modalities and drug delivery in pancreatic cancer - an ongoing search for improved efficacy.
Zhang Y; Satoh K; Li M
Drugs Context; 2012 Dec; 2012():212244. PubMed ID: 24432033
[TBL] [Abstract][Full Text] [Related]
9. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells.
Commisso C; Davidson SM; Soydaner-Azeloglu RG; Parker SJ; Kamphorst JJ; Hackett S; Grabocka E; Nofal M; Drebin JA; Thompson CB; Rabinowitz JD; Metallo CM; Vander Heiden MG; Bar-Sagi D
Nature; 2013 May; 497(7451):633-7. PubMed ID: 23665962
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models.
Feldmann G; Mishra A; Bisht S; Karikari C; Garrido-Laguna I; Rasheed Z; Ottenhof NA; Dadon T; Alvarez H; Fendrich V; Rajeshkumar NV; Matsui W; Brossart P; Hidalgo M; Bannerji R; Maitra A; Nelkin BD
Cancer Biol Ther; 2011 Oct; 12(7):598-609. PubMed ID: 21768779
[TBL] [Abstract][Full Text] [Related]
11. Activated KrasG¹²D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin.
Rachagani S; Senapati S; Chakraborty S; Ponnusamy MP; Kumar S; Smith LM; Jain M; Batra SK
Br J Cancer; 2011 Mar; 104(6):1038-48. PubMed ID: 21364589
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling.
Feldmann G; Mishra A; Hong SM; Bisht S; Strock CJ; Ball DW; Goggins M; Maitra A; Nelkin BD
Cancer Res; 2010 Jun; 70(11):4460-9. PubMed ID: 20484029
[TBL] [Abstract][Full Text] [Related]
13. Trials of gene therapy for pancreatic carcinoma.
Halloran CM; Ghaneh P; Costello E; Neoptolemos JP
Curr Gastroenterol Rep; 2005 Jun; 7(3):165-9. PubMed ID: 15913472
[No Abstract] [Full Text] [Related]
14. Dominant negative inhibitors of signalling through the phosphoinositol 3-kinase pathway for gene therapy of pancreatic cancer.
Stoll V; Calleja V; Vassaux G; Downward J; Lemoine NR
Gut; 2005 Jan; 54(1):109-16. PubMed ID: 15591514
[TBL] [Abstract][Full Text] [Related]
15. p8 inhibits the growth of human pancreatic cancer cells and its expression is induced through pathways involved in growth inhibition and repressed by factors promoting cell growth.
Malicet C; Lesavre N; Vasseur S; Iovanna JL
Mol Cancer; 2003 Nov; 2():37. PubMed ID: 14613582
[TBL] [Abstract][Full Text] [Related]
16. Novel gene therapy approaches to pancreatic cancer.
Katz MH; Bouvet M
Int J Gastrointest Cancer; 2003; 33(1):89-97. PubMed ID: 12909741
[TBL] [Abstract][Full Text] [Related]
17. Hyperstable U1snRNA complementary to the K-ras transcripts induces cell death in pancreatic cancer cells.
Kato K; Hitomi Y; Imamura K; Esumi H
Br J Cancer; 2002 Oct; 87(8):898-904. PubMed ID: 12373606
[TBL] [Abstract][Full Text] [Related]
18. A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells.
Su Z; Lebedeva IV; Gopalkrishnan RV; Goldstein NI; Stein CA; Reed JC; Dent P; Fisher PB
Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10332-7. PubMed ID: 11526239
[TBL] [Abstract][Full Text] [Related]
19. Oligonucleotide treatment of ras-induced tumors in nude mice.
Wickstrom E
Mol Biotechnol; 2001 May; 18(1):35-55. PubMed ID: 11439698
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
